Overexpression of MEKK2 is associated with colorectal carcinogenesis

LI JIANG¹, MEIJIN HUANG², LEI WANG², XINJUAN FAN², PUNING WANG², DAOHAI WANG¹, XINHUI FU² and JIANPING WANG²

¹Department of Gastrointestinal Surgery, Shenzhen People's Hospital, Shenzhen, Guangdong 518020; ²Department of Colorectal Surgery, The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510655; ³Department of General Surgery, Henan Cancer Hospital, Zhengzhou, Henan 450008, P.R. China

Received February 19, 2013; Accepted July 5, 2013

DOI: 10.3892/ol.2013.1553

Abstract. Mitogen-activated protein kinase kinase kinase 2 (MEKK2) is an important upstream mediator of the extracellular signal-regulated kinase 5 signaling cascade that is essential for a number of cellular functions, including mitogenesis, differentiation and oncogenic transformation. Using western blotting to examine MEKK2 expression in 16 cases of primary colorectal cancer (CRC) lesions with paired normal mucosa, it was identified that MEKK2 is highly expressed in CRC lesions compared with that of the normal mucosa. Immunohistochemistry of 24 normal mucosa, 24 adenoma and 96 adenocarcinoma colorectal specimens indicated that the expression of MEKK2 was significantly increased in the adenoma and carcinoma specimens compared with that of the normal mucosa. Immunohistochemistry of 24 normal mucosa, 24 adenoma and 96 adenocarcinoma colorectal specimens indicated that the expression of MEKK2 was significantly increased in the adenoma and carcinoma specimens compared with that of the normal mucosa cases (P<0.0001 for both). However, no significant differences were detected in MEKK2 expression between the carcinoma and adenoma specimens (P=0.85). Similarly, no correlations were identified between MEKK2 expression and clinicopathological features, including gender, age, body mass index, histological differentiation, depth of invasion, lymph node metastasis, UICC stage and K-ras mutations (P>0.05). The present study demonstrated that MEKK2 functions as a promotive factor in CRC.

Introduction

Colorectal cancer (CRC) is the second and third most common type of malignancy in females and males worldwide, respectively (1). In the majority of Asian countries, CRC morbidity has increased rapidly throughout previous decades, and follows a stepwise progression from normal tissue to a premalignant phase to the invasive carcinoma. This process is known as the adenoma-carcinoma sequence. Recently, a number of studies have suggested that the accumulation of multiple gene mutations in key signaling pathways correlates with the multiple steps of colorectal carcinogenesis (2,3). Therefore, it is essential to identify significant molecular biomarkers in these pathways for the prevention and treatment of CRC.

Mitogen-activated protein kinase kinase kinase 2 (MEKK2) is a Ser/Thr protein kinase expressed in multiple tissues that belongs to the MEKK/STE11 subgroup of the MAP3K family (4,5). Specifically, MEKK2 is a member of the extracellular signal-regulated kinase 5 (ERK5) signaling cascade that has been previously identified in all four mitogen-activated protein kinase (MAPK) pathways, including MEKK2/3, MEK5 and ERK5 at the MAP3K, MAPKK and MAPK tiers, respectively (6). The ERK5 signaling cascade is essential for the control of cellular proliferation (7) and is likely to be targeted during cell cycle progression (8,9) and tumorigenesis (10,11). In addition, the ERK5 cascade is involved in the management of cell differentiation (12,13), migration (14,15), neuronal survival rate (16), embryonic angiogenesis (17) and additional cellular functions (18-21).

MEKK2 has been shown to mediate epidermal growth factor and fibroblast growth factor 2 receptor signals (22,23) which have been previously identified to be involved in the development of various types of cancer (24,25). Therefore, MEKK2 may also be important for the development of cancer. However, although overexpression of MEKK2 has been identified in prostate cancer (26), to the best of our knowledge, no studies have analyzed the expression of MEKK2 in CRC. Therefore, the aim of the present study was to determine MEKK2 expression at the protein level in colorectal carcinomas and adenomas, as well as normal epithelial specimens, by immunohistochemistry (IHC), to explore the significance of MEKK2 in the development of CRC. The potential correlation between MEKK2 expression and the major clinicopathological features of CRC and K-ras mutations was also assessed to determine the novel involvement of MEKK2 in the malignant development of CRC.

Materials and methods

Western blot analysis. Sixteen pairs of randomly collected CRC patient and matched non-cancerous tissue specimens

Key words: immunohistochemistry, colorectal cancer, MEKK2, carcinogenesis
were analyzed by western blot analysis. Total protein extracted from frozen colorectal mucosa was resolved using 12% SDS polyacrylamide gel and electrotransferred to a polyvinylidene difluoride membrane (Pall, Port Washington, NY, USA). Following blocking with 5% bovine serum albumin for 1 h, the tissues were incubated with primary rabbit monoclonal antibody against MEKK2 (EP626Y; Abcam, Cambridge, UK) at a dilution of 1:10,000. The immunoreactive bands were detected using enhanced chemiluminescence reagents (GE Healthcare, Uppsala, Sweden). The procedures were conducted according to the manufacturer's instructions and β-actin was used as a loading control.

Tissue samples. Specimens were randomly selected from archival tissues surgically extracted at the Sixth Affiliated Hospital of Sun Yat-sen University (Guangzhou, China) between 2009 and 2010. Tissue samples from the local pathology repository, as well as clinical data were available. Formalin-fixed paraffin-embedded specimens were collected for IHC analysis, including 24 normal epithelial, 24 adenoma and 96 primary adenocarcinoma colorectal specimens, classified as stages I (n=16), II (n=23), III (n=43) and IV (n=14), according to the International Union Against Cancer tumor-node-metastasis (TNM) staging criteria (7th version, 2009). The patient group included 80 males and 64 females with a mean age of 60 years (range, 18-87 years). The present study was approved by the ethics committee of The Sixth Affiliated Hospital of Sun Yat-sen University (Guangzhou, China) and written informed consent was obtained from each participant.

Tissue microarray. Hematoxylin and eosin-stained slides from each tumor block were examined to select a morphologically representative area. Two core tissue biopsies with a diameter of 1 mm were punched from the marked area of each donor block and transferred to the recipient paraffin blocks using the precise Minicore® Tissue Arrayer (Alphelys, Plaisir, France). Three tissue microarrays were constructed, including 8 normal epithelial, 8 adenoma and 32 carcinoma colorectal specimens. The tissue microarray blocks were cut into 4 µm-sections using a microtome, mounted on polylysine-coated glass slides and used for IHC analysis.

IHC. Slides were deparaffinized in xylene and rehydrated using a graded ethanol series. Antigens were retrieved by boiling the slides in a microwave oven for 15 min in 0.01 mol/l citrate buffer (pH 6.0). Endogenous peroxidase was blocked with 0.3% hydrogen peroxide solution and the slides were incubated in 10% normal goat serum for 15 min to prevent nonspecific staining. The tissue sections were then incubated overnight at 4°C with rabbit monoclonal antibody against MEKK2 (EP626Y; Abcam) at a dilution of 1:200. Subsequently, the standard horseradish peroxidase/DAB (Dako Envision+ System; Dako, Carpinteria, CA, USA) method was used and the slides were lightly counterstained with hematoxylin. Positively stained CRC sections were included as negative and positive controls, and sections incubated with antibody diluent instead of the primary antibody were used as negative controls.

Evaluation of IHC. Immunohistochemical staining was examined and evaluated by two independent pathologists. The staining results were scored according to the intensity of staining: 0, negative; 1, bordering; 2, weak; 3, moderate and 4, strong. In addition, the percentage of tumor cells stained was scored: 0, none; 1, 1-25%; 2, 26-50%; 3, 51-75% and 4, 76-100%. Staining index was calculated as follows: staining index = staining intensity score x proportion score. Using this method, the expression of MEKK2 in cores was evaluated by determining the staining index and scores were arranged between 0 and 16. Each specimen provided two cores and the score of each specimen was acquired from their mean values. Tumor specimens were grouped into two categories defined as follows: i) high expression, with an average score of ≥8; and ii) low expression, with an average score of <8.

Statistical analysis. Statistical analyses were performed using SPSS 17.0 for Windows (SPSS, Inc., Chicago, IL, USA). The χ², Kruskal-Wallis or Mann-Whitney U tests were used to analyze the correlation between MEKK2 expression in normal mucosa, adenoma and carcinoma specimens and clinicopathological features. All P-values are two-sided and P<0.05 was considered to indicate a statistically significant difference.

Results

MEKK2 protein expression levels in CRC and normal colorectal tissues. Expression of MEKK2 protein was primarily investigated by western blot analysis in 16 randomly selected pairs of CRC and matched non-cancerous colorectal tissues. MEKK2 protein was overexpressed in 13 (81.3%) tumor tissues, which was significantly higher than that of non-cancerous colorectal tissues (Fig. 1).

MEKK2 expression in adjacent normal mucosa, adenoma and carcinoma. MEKK2 expression was examined by IHC in 24 adjacent normal mucosa, 24 adenoma and 96 carcinoma specimens. Expression was detected in the cytoplasm of normal mucosa and tumor epithelial cells (Fig. 2), but no nuclear staining was identified. Low expression of MEKK2 was identified in all 24 normal mucosa specimens (100%), with no detection of high expression (0%). In the adenomas, 18 (75.0%) specimens exhibited strong expression and 6 (25.0%) exhibited weak expression. In the carcinomas, 80 (83.3%) specimens exhibited strong expression and 16 (16.7%) exhibited weak expression.

A significant difference was identified in the overall distribution of MEKK2 expression among the normal mucosa, adenoma and carcinoma specimens (χ²=61.97; P<0.001; Table 1). High expression of MEKK2 was significantly increased in adenoma (P<0.0001) and carcinoma specimens when compared with that of the normal mucosa specimens (P<0.0001). However, although expression was increased in the adenoma specimens compared with the carcinomas, MEKK2 levels were not found to be significantly different (P=0.85).

Correlation between MEKK2 expression and clinicopathological variables in carcinomas. The correlation between MEKK2 expression in carcinomas and a set of clinicopathological variables were analyzed. However, no significant correlations were observed between MEKK2 expression and
clinicopathological variables, including gender, age, body mass index, histological differentiation, depth of invasion, lymph node metastasis and UICC stage (P>0.05; Table II).

Correlation between MEKK2 expression and K-ras mutations in adenomas and carcinomas. In addition, the correlation between MEKK2 expression and the K-ras mutation state in carcinomas was analyzed, however, no correlation was identified (P=0.68; Table II).

Discussion

The majority of CRCs arise via the adenoma-carcinoma sequence. A number of molecular and pathway alterations have been identified during this process, which are specific to the transformation from normal cells to adenoma, development from adenoma to cancer or the process as a whole (2,3). Analyzing the alterations of molecular biomarkers may aid in the prevention, early diagnosis and treatment of CRC. In the current study, the correlation between MEKK2 expression and clinicopathological features was investigated in various CRC tissues for the first time. The results demonstrate that MEKK2 may be involved in the development of CRC.

As one of the only two upstream molecules in the ERK5 cascade, MEKK2 is crucial in relaying specific cell surface signals to downstream ERK5 following transcription regulation. MEKK2 is distributed in the cytoplasm and forms a complex with the MEKK2-interacting protein, which prevents its activation (27). When cells are stimulated by the epidermal growth factor (EGF) and additional stimuli, the complex dissociates and the number of MEKK2 molecules increases (27). Overexpression of MEKK2 is sufficient for the formation of dimers leading to self-phosphorylation and activation (28). In the present study, free MEKK2 protein was detected in various colorectal tissues, indicating a correlation with the development of CRC. MEKK2 was notably upregulated during the transition from normal epidermal to adenoma, and from adenoma to carcinoma. A significant difference was identified in MEKK2 expression levels between adenoma and carcinoma, indicating that MEKK2 may represent a promotive factor of CRC, which is important for the early stages of CRC development. In addition, inhibition of MEKK2 expression may block the development of CRC and therefore, be significant for the development of colorectal adenoma.

However, in the present study, no correlations were identified between MEKK2 expression and the critical clinicopathological factors of carcinoma, including TNM stage, degree of differentiation and in particular, indicators of CRC foci-invasive and metastatic dissemination capabilities. This
indicates that the correlation between MEKK2 expression and CRC carcinogenesis is negligible; however, MEKK2 may not be excluded as a biomarker for adenoma-carcinoma progression. Similarly, no significant correlation was identified between the expression of MEKK2 and K-ras mutation status. These observations are in accordance with a study by

### Table I. Correlation between MEKK2 expression levels and various colorectal tissues.

|                | Low expression | High expression | P-value |
|----------------|----------------|-----------------|---------|
|                | n   | n   | %    | n   | %    |        |
| n              | 96  |     |      |     |      |         |
| Normal mucosa  | 24  | 24  | 100.0| 0   | 0.0  | <0.001 |
| Adenoma        | 24  | 6   | 25.0 | 18  | 75.0 |        |
| Carcinoma      | 96  | 16  | 16.7 | 80  | 83.3 |        |

MEKK2, mitogen-activated protein kinase kinase kinase 2.

### Table II. Correlation between MEKK2 expression levels and clinicopathological variables of colorectal carcinoma.

| Valuables                  | n | Low expression | High expression | P-value |
|----------------------------|---|----------------|-----------------|---------|
| n                          | 96 |                |                 |         |
| Gender                     |    |                |                 | 0.78    |
| Male                       | 45 | 7              | 84.4            |        |
| Female                     | 51 | 9              | 82.4            |        |
| Age, years-old             |    |                |                 | 1.00    |
| <55                        | 30 | 5              | 83.3            |        |
| ≥55                        | 66 | 11             | 83.3            |        |
| BMI                        |    |                |                 | 0.19    |
| <24.0                      | 67 | 9              | 86.6            |        |
| ≥24.0                      | 29 | 7              | 75.9            |        |
| Histological differentiation|    |                |                 | 0.49    |
| Well                       | 22 | 4              | 81.8            |        |
| Moderate                   | 63 | 9              | 85.7            |        |
| Poor                       | 11 | 3              | 72.7            |        |
| T stage                    |    |                |                 | 0.75    |
| 1                          | 7  | 1              | 85.7            |        |
| 2                          | 17 | 4              | 76.5            |        |
| 3                          | 57 | 8              | 86.0            |        |
| 4                          | 15 | 3              | 80.0            |        |
| N stage                    |    |                |                 | 0.27    |
| 0                          | 42 | 9              | 78.6            |        |
| 1-2                        | 54 | 7              | 87.0            |        |
| UICC stage                 |    |                |                 | 0.42    |
| I                          | 16 | 5              | 68.8            |        |
| II                         | 23 | 3              | 87.0            |        |
| III                        | 43 | 6              | 86.0            |        |
| IV                         | 14 | 2              | 85.7            |        |
| K-ras mutation             |    |                |                 | 0.68    |
| Yes                        | 26 | 5              | 80.8            |        |
| No                         | 70 | 11             | 84.3            |        |

MEKK2, mitogen-activated protein kinase kinase kinase 2; BMI, body mass index; T stage, depth of invasion; N stage, lymph node metastasis.
Kato et al., which reported that EGF-mediated activation of ERK5 proceeds independently of Ras (7).

Currently, the mechanisms responsible for the correlation between MEKK2 expression and the neoplastic process are not yet fully understood and require investigation. The significance of this correlation may be examined via the downstream molecule ERK5, which has been investigated in a number of previous studies. ERK5 functions as a survival rate factor in mitosis (9), and is essential for EGF-mediated cell proliferation and for cells to enter the S phase of the cell cycle (10). In addition, overexpression of ERK5 has been identified in various types of cancer, including breast and prostate cancer and oral squamous cell carcinoma, and has been hypothesized to represent an independent prognostic biomarker of disease-free survival (11,29,30). Therefore, overexpression of MEKK2, as an important upstream mediator, activates ERK5 and initiates the development of CRC.

A limitation of the present study was that the patients were newly diagnosed with CRC in the last two years and were deficient of prognostic data. Therefore, the prognostic value of MEKK2 in CRC has not been assessed and requires investigation in future studies.

In conclusion, the results of the current study indicate that overexpression of MEKK2 correlates with colorectal carcinogenesis and may represent a promotive factor in the development of CRC. Specifically, MEKK2 may be particularly important in the early phases of this stepwise process during the transition from normal epithelium to adenoma. However, future studies must investigate this correlation in detail to evaluate its application.

Acknowledgements

The current study was funded by grants from the National Natural Science Foundation of China (nos. 81072042, 30872448 and 81001108) and the Guangdong Provincial Scientific Research (nos. 8151008901000059 and 10251008901000008).

References

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.

2. Fearon ER and Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 61: 759-767, 1990.

3. Vogelstein B, Fearon ER, Hamilton SR, et al: Genetic alterations during colorectal-tumor development. N Engl J Med 319: 525-532, 1988.

4. Blank JL, Gerwins P, Elliott EM, Sather S and Johnson GL: Molecular cloning of mitogen-activated protein/ERK kinase kinases (MEKK) 2 and 3: Regulation of sequential phosphorylation pathways involving mitogen-activated protein kinase and c-Jun kinase. J Biol Chem 271: 5361-5368, 1996.

5. Su B, Cheng J, Yang J and Guo Z: MEKK2 is required for T-cell receptor signals in JNK activation and interleukin-2 gene expression. J Biol Chem 276: 14784-14790, 2001.

6. Yao Z, Yoon S, Kalic E, Raviv Z and Seger R: Calcium regulation of EGF-induced ERK5 activation: role of Lad1-MEKK2 interaction. PLoS One 5: e12627, 2010.

7. Kato Y, Tapping RI, Huang S, Watson MH, Ulevitch RJ and Lee JD: Bmk1/Erk5 is required for cell proliferation induced by epidermal growth factor. Nature 395: 715-716, 1998.

8. Cude K, Wang Y, Choi HJ, Hsuan SL, Zhang H, Wang CY and Xia Z: Regulation of the G2-M cell cycle progression by the ERK5-NFkappaB signaling pathway. J Cell Biol 177: 253-264, 2007.

9. Girio A, Montero JC, Pandiella A and Chatterjee S: Erk5 is activated and acts as a survival factor in mitosis. Cell Signal 19: 1964-1972, 2007.

10. Robinson G, English JM, White MA and Cobb MH: ERK5 and ERK6 cooperate to regulate NF-kappaB and cell transformation. J Biol Chem 76: 7927-7931, 2001.

11. Montero JC, Ocaña A, Abad M, Ortiz-Ruiz MJ, Pandiella A and Esparis-Ogado A: Expression of Erk5 in early stage breast cancer and association with disease free survival identifies this kinase as a potential therapeutic target. PLoS One 4: e5565, 2009.

12. Carter EJ, Cosgrove RA, Gonzalez I, Eismann JH, Lovett FA, Cobb LJ and Pell JM: MEK5 and ERK5 are mediators of the pro-mygogenic actions of IGF-2. J Cell Sci 122: 3104-3112, 2009.

13. Dinev D, Jordan BW, Neufeld B, Lee JD, Lindemann D, Rapp UR and Ludwig S: Extracellular signal regulated kinase 5 (ERK5) is required for the differentiation of muscle cells. EMBO Rep 2: 829-834, 2001.

14. Schramp M, Ying O, Kim TY and Martin GS: ERK5 promotes Src-induced podosome formation by limiting Rho activation. J Cell Biol 181: 1195-1210, 2008.

15. Spierdink E, Schmolke M, Ohnesorge N, et al: MEK5/ERK5 signaling modulates endothelial cell migration and focal contact turnover. J Biol Chem 284: 24972-24980, 2009.

16. Watson FL, Heerssen HM, Bhattacharyyaa A, Klesse L, Lin MZ and Segal RA: Neurotrophins use the Erk5 pathway to mediate a survival-signal promoting neuronal fate. Nat Neurosci 4: 981-988, 2001.

17. Sohn SJ, Sarvis BK, Cado D and Winoto A: ERK5 MAPK regulates embryonic angiogenesis and acts as a hypoxia-sensitive repressor of vascular endothelial growth factor expression. J Biol Chem 277: 43344-43351, 2002.

18. Nicol RL, Frey N, Pearson G, Cobb M, Richardson J and Olson EN: Activated MEK5 induces serial assembly of sarcomeres and eccentric cardiac hypertrophy. EMBO J 20: 2757-2767, 2001.

19. Liu L, Cundiff P, Abel G, et al: Extracellular signal-regulated kinase (ERK) 5 is necessary and sufficient to specify cortical neuronal fate. Proc Natl Acad Sci USA 103: 9697-9702, 2006.

20. Nishimoto S and Nishida E: MAPK signalling: ERK5 versus ERK1/2. EMBO Rep 7: 782-786, 2006.

21. Wang X and Tournier C: Regulation of cellular functions by the ERK5-signalling pathway. Cell Signal 18: 753-760, 2006.

22. Sun W, Wei X, Kesavan K, et al: MEK kinase 2 and the adaptor protein Lad regulate extracellular signal-regulated kinase 5 activation by epidermal growth factor via Src. Mol Cell Biol 23: 2298-2308, 2003.

23. Kesavan K, Lobel-Rice K, Sun W, Lapadat R, Webb S, Johnson GL and Garrington TP: MEK2 regulates the coordinate activation of ERK5 and JNK in response to FGF-2 in fibroblasts. J Cell Physiol 199: 140-148, 2004.

24. Herbst RS and Shin DM: Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer 94: 1593-1611, 2002.

25. Bilouzet C, Ellikhat N, Thierry JP and Jouanneau J: Targets of fibroblast growth factor 1 (FGF-1) and FGF-2 signaling involved in the invasive and tumorigenic behavior of carcinoma cells. Mol Biol Cell 15: 4725-4734, 2004.

26. Cazares LH, Troyer D, Mendinros S, et al: Imaging mass spectrometry of a specific fragment of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 2 discriminates cancer from uninvolved prostate tissue. Clin Cancer Res 15: 5541-5551, 2009.

27. Cheng J, Zhang D, Kim K, Zhao Y, Zhao Y and Su B: Mipl, an MEKK2-interacting protein, controls MEKK2 dimerization and activation. Mol Cell Biol 25: 981-988, 2005.

28. Cheng J, Yu L, Zhang D, Huang Q, Spencer D and Su B: Dimerization through the catalytic domain is essential for MEKK2 activation. J Biol Chem 280: 13477-13482, 2005.

29. McCracken SR, Ramsay A, Heer R, et al: Aberrant expression of MEKK2-interacting protein, controls MEKK2 dimerization and activation. Mol Cell Biol 25: 981-988, 2005.